Professor Joris Veltman
- Email: email@example.com
- Telephone: 0191 2418611
- Fax: 0191 2418666
- Address: Institute of Genetic Medicine
Newcastle upon Tyne
Director of the Institute of Genetic Medicine at Newcastle University
Professor of Translational Genomics
Royal Society Wolfson Research Merit Award Holder
How is it possible that severe early-onset disorders are mostly genetic in origin, even though the disorders are not inherited because of their effect on fitness? Our research using state-of-the-art genomics approaches in patient-parent trios have recently indicated that most of these disorders are caused by de novo germline mutations, arising mostly in the paternal lineage.
My research has contributed significantly to the understanding of mutational mechanisms underlying severe genetic disorders and to the implementation of genomics approaches in medicine. Early on in my career, my research using genomic microarrays enhanced our understanding of structural genomic variation and its role in intellectual disability and rare syndromes. Following this success we were the first in the world to implement genomic microarrays in diagnostics. More recently, our research using both exome and genome sequencing has provided strong experimental evidence for a de novo paradigm in severe early-onset disorders. We could show that de novo germline mutations, detected by comparing exomes or genomes of patients to that of their unaffected parents, are the major cause of severe intellectual disability. Following this success we implemented exome sequencing in diagnostics in 2011. Last year, diagnostic exome sequencing was performed in more than 5000 patients in Nijmegen. Currently, we are performing clinical utility studies to determine whether we should replace this by genome sequencing. Application of this ultimate genetic test in our research allowed us to start understanding mutational processes and establish links between the occurrence and frequency of these mutations and risk factors. Most notably, work by others and us has clearly demonstrated that advanced paternal age is a risk factor for severe genetic disorders in the offspring.
Since our first publication on the detection of de novo mutations in intellectual disability in 2010, I have focused my research on further understanding the frequency, generation, risk factors and role of these de novo mutations in genetic disease. Specifically, my group and I have moved from studying de novo mutations in the coding region to studying the entire genome. This has provided insight into the presence and role of the different types of de novo mutations in the genome of patients with intellectual disability, from single point mutations to structural rearrangements. Also, we obtained insight into the paternal origin of de novo germline mutations and identified parent-of-origin-specific mutation signatures becoming more pronounced with increased parental age, pointing to different mutational mechanisms in spermatogenesis and oogenesis. Furthermore, we optimized and applied highly sensitive single molecule Molecular Inversion Probe (smMIP) technology to distinguish germline from somatic de novo mutations. This allowed us to demonstrate that an important fraction of de novo mutations presumed to be germline in fact occurred either post-zygotically in the offspring or were inherited from a low-level mosaicism in one of the parents. In the last 2 years I have started to focus my research on the role of de novo mutations in male infertility. For this I have established local, national and international collaborations, obtained informed consent, collected patient samples and hired personnel. We have started the first pilot studies by performing targeted smMIP approaches in 1000 men with unexplained male infertility. In addition, we have started RNA sequencing pilot studies in germ cell populations from FACS sorted testis biopsies of fertile and infertile men.
- Acuna-Hidalgo R, Deriziotis P, Steehouwer M, Gilissen C, Graham SA, van Dam S, Hoover-Fong J, Telegrafi AB, Destree A, Smigiel R, Lambie LA, Kayserili H, Altunoglu U, Lapi E, Uzielli ML, Aracena M, Nur BG, Mihci E, Moreira LMA, Borges Ferreira V, Horovitz DDG, da Rocha KM, Jezela-Stanek A, Brooks AS, Reutter H, Cohen JS, Fatemi A, Smitka M, Grebe TA, Di Donato N, Deshpande C, Vandersteen A, Marques Lourenco C, Dufke A, Rossier E, Andre G, Baumer A, Spencer C, McGaughran J, Franke L, Veltman JA, De Vries BBA, Schinzel A, Fisher SE, Hoischen A, van Bon BW. Overlapping SETBP1 gain-of-function mutations in Schinzel-Giedion syndrome and hematologic malignancies. PLoS Genetics 2017, 13(3), e1006683.
- Acuna-Hidalgo R, Sengul H, Steehouwer M, van de Vorst M, Vermeulen SH, Kiemeney LALM, Veltman JA, Gilissen C, Hoischen A. Ultra-sensitive Sequencing Identifies High Prevalence of Clonal Hematopoiesis-Associated Mutations throughout Adult Life. American Journal of Human Genetics 2017, 101(1), 50-64.
- Smeekens SP, Plantinga TS, van de Veerdonk FL, Heinhuis B, Hoischen A, Joosten LAB, Arkwright PD, Gennery A, Kullberg BJ, Veltman JA, Lilic D, van der Meer JWM, Netea MG. STAT1 hyperphosphorylation and defective IL12R/IL23R signaling underlie defective immunity in autosomal dominant Chronic Mucocutaneous Candidiasis. PLoS One 2011, 6(12), e29248.
- van de Veerdonk FL, Plantinga TA, Hoischen A, Smeekens SP, Joosten LAB, Gilissen C, Arts P, Rosentul DC, Carmichael AJ, van der Graaf CAA, Kullberg BJ, van der Meer JWM, Lilic D, Veltman JA, Netea MG. STAT1 Mutations in Autosomal Dominant Chronic Mucocutaneous Candidiasis. New England Journal of Medicine 2011, 365, 54-61.
- Hoischen A, van Bon BWM, Rodriguez-Santiago B, Gilissen C, Vissers LELM, de Vries P, Janssen I, van Lier B, Hastings R, Smithson SF, Newbury-Ecob R, Kjaergaard S, Goodship J, McGowan R, Bartholdi D, Rauch A, Peippo M, Cobben JM, Wieczorek D, Gillessen-Kaesbach G, Veltman JA, Brunner HG, de Vries BBBA. De novo nonsense mutations in ASXL1 cause Bohring-Opitz syndrome. NATURE GENETICS 2011, 43(8), 729-731.
- Hoischen A, Van Bon B, Gilissen C, Arts P, Van Lier B, Steehouwer M, De Vries P, De Reuver R, Wieskamp N, Mortier G, Devriendt K, Amorim M, Revencu N, Kidd A, Barbosa M, Turner A, Smith J, Oley C, Henderson A, Hayes I, Thompson E, Brunner H, De Vries B, Veltman J. De novo mutations of SETBP1 cause Schinzel-Giedion syndrome. Nature Genetics 2010, 42(6), 483-485.
- Vermeer S, Hoischen A, Meijer RPP, Gilissen C, Neveling K, Wieskamp N, de Brouwer A, Koenig M, Anheim M, Assoum M, Drouot N, Todorovic S, Milic-Rasic V, Lochmuller H, Stevanin G, Goizet C, David A, Durr A, Brice A, Kremer B, van de Warrenburg BPC, Schijvenaars MMVAP, Heister A, Kwint M, Arts P, van der Wijst J, Veltman J, Kamsteeg EJ, Scheffer H, Knoers N. Targeted Next-Generation Sequencing of a 12.5 Mb Homozygous Region Reveals ANO10 Mutations in Patients with Autosomal-Recessive Cerebellar Ataxia. American Journal of Human Genetics 2010, 87(6), 813-819.
- Lugtenberg D, de Brouwer APM, Kleefstra T, Oudakker AR, Frints SGM, Schrander-Stumpel CTRM, Fryns JP, Jensen LR, Chelly J, Moraine C, Turner G, Veltman JA, Hamel BCJ, de Vries BBA, van Bokhoven H, Yntema HG. Chromosomal copy number changes in patients with non-syndromic X linked mental retardation detected by array CGH. Journal of Medical Genetics 2006, 43(4), 362-370.
- Jansen S, Hoischen A, Coe BP, Carvill GL, van Esch H, Bosch DGM, Andersen UA, Baker C, Bauters M, Bernier RA, van Bon BW, Claahsen-van der Grinten HL, Gecz J, Gilissen C, Grillo L, Hackett A, Kleefstra T, Koolen D, Kvarnung M, Larsen MJ, Marcelis C, McKenzie F, Monin M-L, Nava C, Schuurs-Hoeijmakers JH, Pfundt R, Steehouwer M, Stevens SJC, Stumpel CT, Vansenne F, Vinci M, van de Vorst M, Vries PD, Witherspoon K, Veltman JA, Brunner HG, Mefford HC, Romano C, Vissers LELM, Eichler EE, de Vries BBA. A genotype-first approach identifies an intellectual disability-overweight syndrome caused by PHIP haploinsufficiency. European Journal of Human Genetics 2017, Epub ahead of print.
- Wiel L, Venselaar H, Veltman JA, Vriend G, Gilissen C. Aggregation of population-based genetic variation over protein domain homologues and its potential use in genetic diagnostics. Human Mutation 2017, 38(11), 1454-1463.
- Wortmann SB, Timal S, Venselaar H, Wintjes LT, Kopajtich R, Feichtinger RG, Onnekink C, Muhlmeister M, Brandt U, Smeitink JA, Veltman JA, Sperl W, Lefeber D, Pruijn G, Stojanovic V, Freisinger P, v Spronsen F, Derks TGJ, Veenstra-Knol HE, Mayr JA, Rotig A, Tarnopolsky M, Prokisch H, Rodenburg RJ. Biallelic variants in WARS2 encoding mitochondrial tryptophanyl-tRNA synthase in six individuals with mitochondrial encephalopathy. Human Mutation 2017, 38(12), 1786-1795.
- Nicolas G, Charbonnier C, Campion D, Veltman JA. Estimation of minimal disease prevalence from population genomic data: Application to primary familial brain calcification. American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics 2017, 177(1), 68-74.
- Lelieveld SH, Wiel L, Venselaar H, Pfundt R, Vriend G, Veltman JA, Brunner HG, Vissers LELM, Gilissen C. Spatial Clustering of de Novo Missense Mutations Identifies Candidate Neurodevelopmental Disorder-Associated Genes. American Journal of Human Genetics 2017, 101(3), 478-484.
- Oud MS, Ramos L, O'Bryan MK, Mclachlan RI, Okutman O, Viville S, de Vries PF, Smeets DF, Lugtenberg D, Hehir-Kwa JY, Gilissen C, van de Vorst M, Vissers LE, Hoischen A, Meijerink AM, Fleischer K, Veltman JA, Noordam MJ. Validation and application of a novel integrated genetic screening method to a cohort of 1,112 men with idiopathic azoospermia or severe oligozoospermia. Human Mutation 2017, Epub ahead of print.